Lv15
100 积分 2022-10-17 加入
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis
2天前
已完结
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
3天前
已完结
Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis ( ADVISE )
3天前
已完结
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
4天前
已完结
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
4天前
已完结
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
6天前
已完结
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)
7天前
已完结
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
7天前
已完结
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
8天前
已完结
Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
8天前
已完结
皖公网安备34019202002308
